On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update. In June 2024, the company announced that EB05 was selected by the Biomedical Advanced Research and Development Authority (BARDA) for evaluation in a U.S. government-funded clinical trial in hospitalized adult patients with acute respiratory distress syndrome (ARDS). The data from this study could provide additional support for expanding the use of EB05, with the ultimate goal being an approval for EB05 as a standard-of-care therapy for all-cause ARDS.
